Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues

Journal of Medicinal Chemistry

Volumn 54, Issue 6, 2011, Pages 1927-1942

  Diez Torrubia, Alberto ^a   Balzarini, Jan ^b   Andrei, Graciela ^b   Snoeck, Robert ^b   De Meester, Ingrid ^c   Camarasa, María José ^a   Velázquez, Sonsoles ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2' DEOXY 3',5' BIS O VALYLPROLYLVALYL BETA DEXTRO RIBOFURANOSYL) 6 (4 PENTYLPHENYL) 2,3 DIHYDROFURO[2,3 D]PYRIMIDIN 2 ONE; 3 [2' DEOXY 3' O (VALYLPROLYLVALYL) BETA DEXTRO RIBOFURANOSYL] 6 (4 PENTYLPHENYL) 2,3 DIHYDROFURO[2,3 D]PYRIMIDIN 2 ONE; 3 [2' DEOXY 5' O (LYSYLPROLYLVALYL) BETA DEXTRO RIBOFURANOSYL] 6 (4 PENTYLPHENYL) 2,3 DIHYDROFURO[2,3 D]PYRIMIDIN 2 ONE; 3 [2' DEOXY 5' O (VALYLPROLYLALANYL) BETA DEXTRO RIBOFURANOSYL] 6 (4 PENTYLPHENYL) 2,3 DIHYDROFURO[2,3 D]PYRIMIDIN 2 ONE; 3 [2' DEOXY 5' O (VALYLPROLYLLEUCYL) BETA DEXTRO RIBOFURANOSYL] 6 (4 PENTYLPHENYL) 2,3 DIHYDROFURO[2,3 D]PYRIMIDIN 2 ONE; 3 [2' DEOXY 5' O (VALYLPROLYLPHENYLALANYL) BETA DEXTRO RIBOFURANOSYL] 6 (4 PENTYLPHENYL) 2,3 DIHYDROFURO[2,3 D]PYRIMIDIN 2 ONE; 3 [2' DEOXY 5' O (VALYLPROLYLVALYL) BETA DEXTRO RIBOFURANOSYL] 6 (4 PENTYLPHENYL) 2,3 DIHYDROFURO[2,3 D]PYRIMIDIN 2 ONE; 3 [5' O (ASPARAGYLPROLYLVALYL) 2' DEOXY BETA DEXTRO RIBOFURANOSYL] 6 (4 PENTYLPHENYL) 2,3 DIHYDROFURO[2,3 D]PYRIMIDIN 2 ONE; 3 [5' O (ASPARTYLPROLYLVALYL) 2' DEOXY BETA DEXTRO RIBOFURANOSYL] 6 (4 PENTYLPHENYL) 2,3 DIHYDROFURO[2,3 D]PYRIMIDIN 2 ONE; DIPEPTIDYL PEPTIDASE IV; PYRIMIDINE NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; SINGLE DRUG DOSE; VARICELLA ZOSTER VIRUS;

ADAMANTANE; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CATTLE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG STABILITY; FEMALE; FURANS; HERPESVIRUS 3, HUMAN; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; HYDROLYSIS; MICE; NITRILES; NUCLEOSIDES; OLIGOPEPTIDES; PRODRUGS; PYRIMIDINES; PYRROLIDINES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; WATER;

EID: 79952804849     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101624e     Document Type: Article

References (37)

1. Fox, D. A.; Hussey, R. E.; Fitzgerald, K. A.; Acuto, O.; Poole, C.; Palley, L.; Daley, J. F.; Schossman, S. F.; Reinhert, E. L. Ta1, a novel 105 kDa human T cell activation antigen defined by a monoclonal antibody J. Immunol. 1984, 133, 1250-1256 (Pubitemid 14060073)
2. De Meester, I.; Vanhoof, G.; Lambeir, A.-M.; Scharpe, S. CD26, let it cut or cut it down Immunol. Today 1999, 20, 367-375 (Pubitemid 29356431)
3. Lambeir, A.-M.; Durinx, C.; Scharpe, S.; De Meester, I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions and clinical aspects of the enzyme DPPIV Crit. Rev. Clin. Lab. Sci. 2003, 40, 209-294 (Pubitemid 36775376)
4. Yaron, A.; Naider, F. Proline-dependent structural and biological properties of peptides and proteins Crit. Rev. Biochem. Mol. 1993, 28, 31-81 (Pubitemid 23065603)
5. Mentlein, R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regul. Pept. 1999, 85, 9-24 (Pubitemid 29505281)
6. Mentlein, R. Cell-surface peptidases. Cell-surface peptidases Int. Rev. Cytol. 2004, 235, 165-202
7. 2) Int. J. Biochem. Cell Biol. 2004, 36, 1848-1859 (Pubitemid 38748537)
8. García-Aparicio, C.; Bonache, M.-C.; De Meester, I.; San-Félix, A.; Balzarini, J.; Camarasa, M.-J.; Velázquez, S. Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach J. Med. Chem. 2006, 49, 5339-5351 (Pubitemid 44260228)
9. García-Aparicio, C.; Diez-Torrubia, A.; Balzarini, J.; Lambeir, A.-M.; Velázquez, S.; Camarasa, M.-J. Efficient conversion of tetrapeptide-based TSAO prodrugs to the parent drug by dipeptidyl-peptidase IV (DPPIV/CD26) Antiviral Res. 2007, 76, 130-139 (Pubitemid 47410317)
10. Balzarini, J.; Pérez-Pérez, M. J.; San-Félix, A.; Schols, D.; Perno, C. F.; Vandamme, A. M.; Camarasa, M. J.; De Clercq, E. 2′,5′-Bis- O -(tert -butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1′-,2″-oxathiole-2′-,2″-dioxide) pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 4392-4396
11. Camarasa, M. J.; Pérez-Pérez, M. J.; San-Félix, A.; Balzarini, J.; De Clercq, E. 3-Spironucleosides (TSAO derivatives), a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of 3′-spiro-5″-[4″-amino-1′-, 2″-oxathiole-2′-,2″-dioxide]pyrimidine nucleosides J. Med. Chem. 1992, 35, 2721-2727
12. Camarasa, M. J.; San-Félix, A.; Velázquez, S.; Pérez-Pérez, M. J.; Gago, F.; Balzarini, J. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase Curr. Top. Med. Chem. 2004, 4, 945-963 (Pubitemid 38864692)
13. Diez-Torrubia, A.; García-Aparicio, C.; Cabrera, S.; De Meester, I.; Balzarini, J.; Camarasa, M. J.; Velázquez, S. Application of the dipeptidyl-peptidase IV (DPPIV/CD26)-based prodrug approach to different amine-containing drugs J. Med. Chem. 2010, 53, 559-572
14. McGuigan, C.; Yarnold, C. J.; Jones, G.; Velázquez, S.; Barucki, H.; Brancale, A.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base J. Med. Chem. 1999, 42, 4479-4484 (Pubitemid 29530003)
15. McGuigan, C.; Barucki, H.; Blewet, S.; Carangio, A.; Erichsen, J. T.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain J. Med. Chem. 2000, 43, 4993-4997 (Pubitemid 32039020)
16. Mc Guigan, C.; Balzarini, J. Aryl furano pyrimidines, the most potent and selective anti-VZV agents reported to date Antiviral Res. 2006, 71, 149-153 (Pubitemid 44226487)
17. McGuigan, C.; Pathirana, R. N.; Migliore, M.; Adak, V.; Luoni, G.; Jones, A. T.; Diez-Torrubia, A.; Camarasa, M. J.; Velázquez, S.; Henson, G.; Snoeck, R.; Andrei, G.; Balzarini, J. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus J. Antimicrob. Chemother. 2007, 60, 1316-1330 (Pubitemid 350168329)
18. McGuigan, C.; Balzarini, J. FV100 as a new approach for the possible treatment of varicella-zoster virus infection J. Antimicrob. Chemother. 2009, 64, 671-673
19. Colla, L.; De Clercq, E.; Busson, R.; Vanderhaeghe, H. Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy) methyl]guanine] J. Med. Chem. 1983, 26, 602-604 (Pubitemid 13162311)
20. Beauchamp, L. M.; Orr, G. F.; De Miranda, P.; Burnette, T.; Krenitsky, T. A. Amino acid ester prodrugs of acyclovir Antivir. Chem. Chemother. 1992, 3, 157-164
21. Beutner, K. R. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy Antiviral Res. 1995, 28, 281-290
22. MacDougall, C.; Guglielmo, B. J. Pharmacokinetics of valacyclovir J. Antimicrob. Chemother. 2004, 53, 899-901
23. Cocohoba, J. M.; McNicholl, I. R. Valganciclovir: an advance in cytomegalovirus therapeutics Ann. Pharmacother. 2002, 6, 1075-1079 (Pubitemid 34564394)
24. Montero, J.-L.; Criton, M.; Dewynter, G.-F.; Imbach, J.-L. Aminoacylation of nucleosides. Mitsunobu conditions versus chemoenzymatic route Tetrahedron Lett. 1991, 32 (39) 5357-5358
25. Wei, Y.; Pei, D. Activation of antibacterial prodrugs by peptide deformylase Bioorg. Med. Chem. 2000, 10, 1074-1076
26. Reynolds, A. J.; Kassiou, M. Recent advances in the Mitsunobu reaction: modifications and applications to biologically active molecules Curr. Org. Chem. 2009, 13 (16) 1610-1632
27. Dandapani, S.; Curran, D. P. Separation-friendly Mitsunobu reactions: a microcosm of recent developments in separation strategies Chem. - Eur. J. 2004, 10, 310-3138
28. Pelletier, J. C.; Kincaid, S. Mitsunobu reaction modifications allowing product isolation without chromatography: application to small parallel library Tetrahedron Lett. 2000, 797-800 (Pubitemid 30089881)
29. Woo, R. B.; Meyer, Jr.; Gamper, H. B. G/C-modified oligodeoxynucleotides with selective complemantarity: synthesis and hybridization properties Nucleic Acids Res. 1996, 24, 2470-2475 (Pubitemid 26237142)
30. McGuigan, C.; Pathirana, N.; Jonse, G.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J. Antiviral Chem. Chemother. 2000, 11, 343-348
31. Loakes, D.; Brown, D. M.; Salisbury, S. A.; McDougall, M. G.; Neagu, C.; Nampalli, S.; Kumar, S. Synthesis and some biochemical properties of a novel 5,6,7,8-tetrahydropyrimido[4,5- c ]pyridazine nucleoside Helv. Chim. Acta 2003, 86, 1193-1204 (Pubitemid 36644472)
32. Friedrich-Bochnitschek, S.; Waldmann, H.; Kunz, H. Allyl esters as carboxy protecting groups in the synthesis of O -glycopeptides J. Org. Chem. 1989, 54, 751-756
33. Deziel, R. Mild palladium(0)-catalyzed deprotection of allyl esters. A useful application in the synthesis of carbapenems and other -lactam derivatives Tetrahedron Lett. 1987, 28 (38) 4371-4372 (Pubitemid 17124703)
34. Dessolin, M.; Guillerez, M. C.; Thieriet, N.; Guibé, F.; Loffet, A. New allyl group acceptors for palladium catalyzed removal of allylic protections and transacylation of allyl carbamates Tetrahedron Lett. 1995, 36, 5741-5744
35. Scheen, A. J. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions Clin. Pharmacokinet. 2010, 49, 573-588
36. Gerich, J. DPP-4 inhibitors: what may be the clinical differentiators- Diabetes Res. Clin. Pract. 2010, 90, 131-140
37. Keating, G. M. Vildagliptin: a review of its use in type 2 diabetes mellitus Drugs 2010, 70, 2089-2112